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Objectives The aim of this study was to systematically review the medical literature to evaluate the impact of AV nodal ablation
in patients with heart failure and coexistent atrial fibrillation (AF) receiving cardiac resynchronization therapy (CRT).
Background CRT has a substantial evidence base in patients in sinus rhythm with significant systolic dysfunction, symptom-
atic heart failure, and prolonged QRS duration. The role of CRT is less well established in AF patients with coexis-
tent heart failure. AV nodal ablation has recently been suggested to improve outcomes in this group.
Methods Electronic databases and reference lists through September 15, 2010, were searched. Two reviewers indepen-
dently evaluated citation titles, abstracts, and articles. Studies reporting the outcomes after AV nodal ablation in
patients with AF undergoing CRT for symptomatic heart failure and left ventricular dyssynchrony were selected.
Data were extracted from 6 studies, including 768 CRT-AF patients, composed of 339 patients who underwent
AV nodal ablation and 429 treated with medical therapy aimed at rate control alone.
Results AV nodal ablation in CRT-AF patients was associated with significant reductions in all-cause mortality (risk ratio:
0.42 [95% confidence interval: 0.26 to 0.68]), cardiovascular mortality (risk ratio: 0.44 [95% confidence interval:
0.24 to 0.81]), and improvement in mean New York Heart Association functional class (risk ratio: –0.52
[95% confidence interval: –0.87 to –0.17]).
Conclusions AV nodal ablation was associated with a substantial reduction in all-cause mortality and cardiovascular mortality and
with improvements in New York Heart Association functional class compared with medical therapy in CRT-AF pa-
tients. Randomized controlled trials are warranted to confirm the efficacy and safety of AV nodal ablation in this pa-
tient population. (J Am Coll Cardiol 2012;59:719–26) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.891Atrial fibrillation (AF) and heart failure (HF) are common
and linked clinical conditions. The development of AF in
patients with HF may significantly affect HF outcomes.
Population data from Framingham suggest that new-onset
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of 1.6 in men and 2.7 in women (1).
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Cardiac resynchronization therapy (CRT) has become
established as an important therapy for HF patients in sinus
rhythm (SR) with left ventricular ejection fraction (LVEF)
35%, ventricular dyssynchrony (assessed by QRS duration
120 ms), and advanced New York Heart Association
(NYHA) functional class (III to IV) (2–4). The role of
CRT in patients with coexistent HF and AF is considered
to be less well defined (5). In AF patients, the evidence base
for CRT has been predominantly derived from observa-
tional case series (6–14), with only limited randomized
controlled trial data in studies enrolling CRT-AF patients
(15,16). Two recent meta-analyses have evaluated CRT out-
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(CRT-AF) compared with those
in SR (CRT-SR) (17,18). When
considered as a group, CRT-AF
patients have experienced, at best,
mixed results for mortality and
functional capacity, with higher
rates of nonresponse, compared
with CRT-SR patients (17,18).
Despite this relatively limited sup-
porting evidence, CRT has gained
increasing acceptance as a useful
therapeutic adjunct in patients
with coexistent HF and AF. A
recent 140-center European sur-
vey, for example, identified that
23% of patients receiving CRT implants had coexistent AF
(19). Current guidelines from the American College of Car-
diology/American Heart Association/Heart Rhythm Society
and the European Society of Cardiology (Class IIa, Level of
Evidence: B) endorse the use of CRT in AF patients with
LVEF 35% and ventricular dyssynchrony. However, both
uidelines advise that AV nodal ablation (AVNA) may be
equired to ensure complete biventricular capture in patients
ith AF (2,3).
The effectiveness of biventricular capture during AF has
een suggested as an important limitation to CRT in AF
atients, with a recent 12-lead Holter study suggesting a
igh prevalence of fusion and pseudo-fusion beats in this
roup (20). In this context, a role for AVNA has been
dvocated to ensure complete synchronized biventricular
apture (7,11,14,17,21,22). Acceptance of this approach has
een limited, however, perhaps because AVNA results in
ermanent pacemaker dependency (14). To determine the
ole of adjunctive AVNA in AF patients with LVEF35%
and QRS duration 120 ms receiving CRT for HF, we
erformed a systematic review of the literature. Our goal
as to evaluate the impact of adjunctive AVNA in this
etting on mortality, left ventricular function, and functional
apacity in this group of patients.
ethods
e searched PubMed, Scopus, Embase, Database of Ab-
tracts of Reviews of Effects, and Cochrane Database of
ystematic Reviews, using the search terms “cardiac resyn-
hronization OR biventricular AND atrial fibrillation.”
his search was supplemented by hand-searching of bibli-
graphies of published studies, as well as reviews of AF and
F. Citations were included if they involved patients with
oexistent HF and AF patients undergoing CRT, and
eported outcomes for medically treated AF patients sepa-
ate from those treated with AVNA. No pre-specified
imitation was placed on the approach to cardiac resynchro-
ization. Studies were accepted if they included patients
Abbreviations
and Acronyms
AF  atrial fibrillation
AVNA  AV nodal ablation
BVP  biventricular pacing
CI  confidence interval
CRT  cardiac
resynchronization therapy
HF  heart failure
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
RR  risk ratioith left ventricular systolic dysfunction, defined as LVEF35%, and QRS width120 ms. No limitation on NYHA
functional class was pre-specified. Individual case reports,
editorials, and review articles were excluded. Studies con-
taining 10 patients or in any treatment group were
excluded. The search was conducted on September 15,
2010. Citations were appraised by independent reviewers
(A.G.B. and A.N.G.), with differences resolved by consen-
sus. Citations from journals in languages other than English
were not included. Selected publications were analyzed for
the following outcomes: all-cause mortality; cardiovascular
mortality; changes in LVEF assessed by objective criteria;
and changes in functional capacity assessed by using objec-
tive criteria such as the 6-min walk test. Mortality data
clarification was obtained for 1 study from the authors (10).
Figure 1 shows the number and reasons for exclusion of
publications from the originally retrieved group of citations.
Statistical analysis. Studies reporting outcomes with ho-
mogenous characteristics were grouped for analysis. When
2 unique studies reported outcomes with homogenous
characteristics, meta-analysis was performed. Mean differ-
Figure 1 Search Flow Diagram for Studies
Included in This Systematic Review
From a total of 555 citations identified by the preliminary search, 6 studies
were selected for inclusion in this review. AF  atrial fibrillation; AVNA 
AF patients undergoing CRT for heart failure who had undergone AVNA;
AVNA–  AF patients who did not have AVNA; CRT  cardiac resynchronization
therapy; LVEF  left ventricular ejection fraction.
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February 21, 2012:719–26 Cardiac Resynchronization Therapy in Atrial Fibrillationences were calculated for continuous variables, and risk
ratios (RRs) were calculated for dichotomous variables. For
each mean difference and risk difference, 95% confidence
intervals (CIs) were evaluated. Pooled estimates were of
differences and RRs were combined with random-effects
models. Homogeneity was assessed with the I2 statistic.
Statistical analysis was performed with Comprehensive
Meta-Analysis software, version 2 (Biostat, Englewood,
New Jersey).
Results
Search and synthesis of literature. There were 555 unique
citations identified after the initial literature search was
combined with supplementary hand-searches; 525 were
excluded on general criteria, and 30 were selected for
secondary review (Fig. 1). From this group, 6 studies were
selected that separately reported outcome data for AF
patients undergoing CRT for HF who had undergone
AVNA (AVNA), compared with those who had not
(AVNA–) (Fig. 1, Table 1) (6,7,10,11,13,14). Five of the 6
studies included data on CRT-SR patients as well as
CRT-AF patients (6,7,10,11,13). One of the 6 studies
solely reported outcome data for CRT-AF patients (14).
For the purpose of this systematic review, we extracted the
data on CRT-AF patients.
Included studies were published in the years 2004
through 2010. With the exception of the MILOS Registry
(11) and the SPARE (Spanish Atrial Fibrillation and
Resynchronization) study (13), which were multicenter
observational series, all included studies were cohorts re-
cruited from 1 or 2 centers only (Table 1) (6,7,10,14). The
studies included 768 AF patients, including 339 who
underwent additional AVNA and 429 patients who were
treated with rate-controlling medication alone. Study size
varied considerably, from small (Molhoek et al. [6], 30
CRT-AF patients) to much larger studies (Gasparini et al.
[11], 243 CRT-AF patients) (Table 1). Three studies
consisted solely of permanent AF patients (7,11,13). One
study included persistent AF lasting 3 months (6). One
study did not report the breakdown according to AF
subtype (10).
Study quality was limited in that 4 of the included studies
were retrospective with only 2 prospective cohort studies.
No randomized controlled trial data were available. Study
inclusion criteria were generally similar across all studies,
including patients with LVEF 35%, ventricular dyssyn-
chrony (assessed by QRS duration 120 ms), and advanced
YHA functional class (Table 1). Patients were generally
ndergoing accepted medical therapy for HF, including use
f beta-blockers, angiotensin-converting enzyme inhibitors,
ldosterone antagonists, and diuretics (6,7,10,11,13,14).
To further assess study quality, we classified study method
y using a composite of features derived from the Newcastle-
ttawa Scale, which has been used to assess quality inonrandomized studies (23). Detailed data are presented inhe Appendix. Case definition was mostly performed by
ndividual treating clinicians in study centers, with the
ajority of studies reporting consecutive recruitment. Sig-
ificant differences were noted in baseline characteristics in
studies (11,13,14). Outcome data were limited in that the
ajority of studies involved nonblinded clinical follow-up,
ith limited descriptions of the completeness of follow-up.
election of CRT-AF patients for AVNA. The method
f selection of patients for AVNA varied between the
tudies. In 4 studies, AVNA was undertaken in patients
ho did not have adequate rate control with medical
herapy, but detailed information regarding decision making
or AVNA was generally not reported (6,10,13,14). In the
ther 2 studies, a systematic selection process was applied to
elect patients for AVNA. Patients with AF were evaluated
or percentage of biventricular pacing (BVP%) after the
mplantation of their CRT device (7,11). If BVP% was
85%, it was recommended that the patient undergo
VNA.
ffectiveness of ventricular rate control in patients
reated with medical therapy. We attempted to extract
ata for effectiveness of ventricular rate control in AVNA
nd AVNA– patients, but this was not available in any of
he retrieved studies. The only study to consider the issue of
entricular rate control was that of Dong et al. (14), who
onsidered heart rate parameters as variables in a univariate
odel. Neither electrocardiogram nor Holter average heart
ates were statistically important predictors of survival in
his study.
ffectiveness of biventricular capture. Effectiveness of
iventricular capture was described in all studies according
o the percentage of biventricular capture from device
iagnostics. In AVNA patients, biventricular capture was
ear to complete. In AVNA– patients, BVP% varied from
2% (6) to 96.5% (14) (Table 1). Only 1 study reported the
se of ventricular rate regularization as a routine part of
evice programming to enhance biventricular capture in
RT-AF patients (7). The use of this algorithm was not
eported in the other studies.
mpact of AV nodal ablation on mortality in CRT-AF
atients. Overall, 3 studies reported mortality data com-
aring CRT-AF patients undergoing AVNA with those
ith pharmacological rate control (10,11,14). All-cause
ortality data in CRT-AF patients undergoing AVNA
ompared with those receiving medical therapy were avail-
ble for 3 studies (Fig. 2) (10,11,14). Eighty-six deaths were
eported from 450 CRT-AF patients in these studies
11,14). RRs were calculated using numbers of deaths for
VNA and AVNA– patients, respectively. The RR for
ll-cause mortality in AF patients undergoing AVNA was
.42 (95% CI: 0.26 to 0.68; p  0.001) (Fig. 2). Between-
tudy heterogeneity for all-cause mortality was low (I2 
0.00). Cardiovascular mortality was reported in Gasparini et
al. (11) and Ferreira et al. (10). The RR for cardiovascular
mortality for CRT-AF patients undergoing AVNA was
0.44 (95% CI: 0.24 to 0.81; p  0.01) (Fig. 3). Between-
Six Studies Reporting Outcome Data for AF Patients Undergoing CRT for HFTable 1 Six Studies Reporting Outcome Data for AF Patients Undergoing CRT for HF
First Author,
Year Study Type n Inclusion Criteria
Comparator
Intervention Groups n Age (yrs) Male (%) AF Characteristics Follow-Up %BVP
Molhoek, 2004 Prospective single-center
cohort
60 Drug-refractory NYHA III–IV
heart failure, LVEF 35%,
QRS duration 120 ms
CRT-SR 30 68 8 80 100% long-standing
persistent AF
(3 months)
6 months Not reported
CRT-AF-AVNA 17 63 10* 90 100%
CRT-AF-AVNA 13 82%
Gasparini, 2006 Prospective 2-center
cohort
673 Drug-refractory NYHA II
heart failure, LVEF 35%,
QRS duration 120 ms
CRT-SR 511 85 100% permanent AF 25.2 18 months 98.5 1.8%
CRT-AF-AVNA 114 66* 98.4 2.1%
CRT-AF-AVNA 48 88.2 3.1%
Ferreira, 2008 Retrospective single-center
cohort
131 Drug-refractory NYHA II–IV
heart failure, LVEF 35%,
QRS duration 120 ms
CRT-SR 78 66 10 74 Not listed for each
subgroup
6 months 95 13%
CRT-AF-AVNA 26 67 9 92 98 6%
CRT-AF-AVNA 27 70 8 96 87 19%
Gasparini, 2008 Retrospective multicenter
registry cohort
1,285 Not pre-specified CRT-SR 1,042 63 10 75 100% permanent AF Median follow-up
34 months
Not reported
CRT-AF-AVNA 118 66 9 78 98.7 1.8%
CRT-AF-AVNA 125 67 9 84 89.4 2.4%
Tolosana, 2008 Retrospective multicenter
cohort
470 Drug-refractory NYHA III–IV
heart failure, LVEF 35%,
QRS duration 120 ms
CRT-SR 344 67 9 76 100% permanent AF 12 months Not reported
CRT-AF-AVNA 19 70 7 81 100%
CRT-AF-AVNA 107 68 10 92 7%
Dong, 2010 Retrospective single-center
cohort
154 Heart failure symptoms
despite medical therapy,
LVEF 35%, QRS
duration 120 ms
CRT-AF-AVNA 45 72 9 84 88% permanent AF Median follow-up
274 days
99.0%
(95% CI: 95%–100%)
CRT-AF-AVNA 109 68 11 87 Median follow-up
222 days†
96.5%
(95% CI: 85.5%–99%)
*Represents mean age of CRT-AF patients as a group. †24% lost to follow-up.
AF  atrial fibrillation; AVNA  patients who had undergone AV nodal ablation; AVNA–  patients who did not undergo AV nodal ablation; BVP%  percentage biventricular pacing; CI  confidence interval; CRT  cardiac resynchronization therapy; HF  heart failure;
NYHA  New York Heart Association; LVEF  left ventricular ejection fraction; SR  sinus rhythm.
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(I2  0.00).
mpact of AV nodal ablation on LVEF in CRT-AF
atients. We identified 3 studies that evaluated the impact
f AVNA on LVEF in 346 CRT-AF patients (Fig. 4)
6,7,14). In these studies, LVEF increased in both
RT-AF AVNA and AVNA– patients after CRT. The
ean increase in LVEF was 4.2% (95% CI: –1.2% to 9.6%)
n AVNA– patients and 10.3% (95% CI: 6.4% to 14.2%) in
VNA patients. The pooled mean difference in LVEF
mprovement favored AVNA patients (6.1% [95% CI:
3.5% to 15.8%]; p  0.2) but was not statistically signif-
cant (Fig. 4). There was significant heterogeneity for this
utcome (I2  0.94).
Impact of AVNA on functional outcomes in CRT-AF
patients. Three studies reported the effect of AVNA on
NYHA functional class in 346 CRT-AF patients (Fig. 5)
(6,7,14). NYHA functional class improved in both AVNA–
(pooled change –0.45 [95% CI: –0.65 to –0.25]) and
AVNA patients (pooled change –0.81 [95% CI: –0.99 to
–0.63]) (Table 2). However, NYHA functional class im-
Figure 2
Risk Ratios for All-Cause Mortality in
CRT-AF Patients Undergoing AVNA Versus
Medical Therapy With Rate-Controlling Drugs
All-cause mortality data were available for 3 studies, comprising 450
patients. The risk ratio for all-cause mortality was 0.42 (95% confidence
interval: 0.26 to 0.68; p  0.001), favoring patients undergoing AVNA.
Abbreviations as in Figure 1.
Figure 3
Risk Ratios for Cardiovascular Mortality
for CRT-AF Patients Undergoing AVNA Versus
Medical Therapy With Rate-Controlling Drugs
Cardiovascular mortality data were available for 2 studies. The risk ratio for
cardiovascular mortality was 0.44 (95% confidence interval: 0.24 to 0.81;
p  0.008). Abbreviations as in Figure 1.proved more in AVNA than in AVNA– patients, with a
mean difference of –0.34 (95% CI: –0.56 to –0.13; p 
0.002) (Table 2, Fig. 5). The I2 statistic for this outcome
was 0.59.
Six-min walk test times were reported in 2 studies (Table 2).
Molhoek et al. (6) reported a significant increase in
6-min walking distance, from 229  125 m to 388  172 m
in AVNA patients (p  0.05) (Table 2). In contrast,
Tolosana et al. (13) did not find a significant change in
6-min walking distance in AVNA patients compared with
AVNA– patients.
Discussion
The most important finding of this study was the decisive
all-cause mortality and cardiovascular mortality advantage
of AVNA in CRT-AF patients. In the 3 studies reporting
mortality data, AVNA conferred an RR for overall mortality
of 0.42; for cardiovascular mortality, the RR was 0.44. The
studies reporting mortality data were the largest, containing
a minimum of 20 patients in each study arm (Table 1)
(10,11,14). Furthermore, the finding seemed to be consis-
Figure 4
Mean Difference in LVEF for
CRT-AF Patients Undergoing AVNA Versus
Medical Therapy With Rate-Controlling Drugs
The pooled mean difference in LVEF improvement favored AVNA patients
(6.1% [95% CI: –3.5% to15.8%]; p  0.2) but was not statistically significant.
Abbreviations as in Figure 1.
Figure 5
Mean Difference in NYHA Functional Class
for CRT-AF Patients Undergoing AVNA Versus
Medical Therapy With Rate-Controlling Drugs
The pooled NYHA functional class improved more in AVNA than in AVNA–
patients, with a mean difference of –0.34 (95% confidence interval: –0.56 to
–0.13, p  0.002). NYHA  New York Heart Association; other abbreviations
as in Figure 1.
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Heterogeneity was low for this outcome. The mortality find-
ings are particularly striking, when considered in the context of
the all-cause mortality benefit in CRT-SR patients. In a
meta-analysis of SR patients, the all-cause mortality RR with
CRT was 0.78 (95% CI: 0.67 to 0.91) (4).
AVNA was also associated with a significant improve-
ment in NYHA functional class in studies reporting this
outcome. The mean difference in NYHA functional class
was –0.34, which favored AVNA patients (Fig. 5). Other
studies used different measures of functional capacity, with
the majority of studies favoring AVNA patients. Six-
minute walking distance was reported in 2 studies. Molhoek
et al. (6) found a statistically significant increase in AVNA
atients compared with AVNA– patients (Table 2). To-
osana et al. (13) identified an increase of 99  220 m in
-min walking distance in AVNA patients compared with
13  31 m in AVNA– patients, but statistical significance
as not reported (Table 2). Significantly larger improve-
ents in functional capacity measures were noted in two-
hirds of studies reporting these outcomes (Table 2) (6,7).
erreira et al. (10) reported functional outcomes in terms of
he percentage of “responders” to CRT, defined as the
ercentage of patients surviving with an improvement of1
YHA functional class at 6 months. AVNA patients had
a significantly higher percentage of responders (85% vs.
62%) than AVNA– patients (10). Gasparini et al. (7) also
reported a higher percentage of responders, defined here as
the percentage of patients showing a10% reduction in left
ventricular end-systolic volume, among AVNA patients
compared with AVNA– patients.
Interestingly, the improvements in mortality and func-
tional capacity with AVNA were not accompanied by a
significant LVEF improvement, with a nonsignificant in-
crease in LVEF among AVNA patients compared with
AVNA– patients. There was significant heterogeneity for
this outcome (I2  0.94). The study heterogeneity seemed
o be driven by the study of Gasparini et al. (7), which
howed a sharp increase in LVEF in CRT-AF patients
eceiving AVNA, a finding that was not observed in the
ther 2 studies reporting LVEF (6,14). Interestingly, these
studies revealed findings favoring AVNA with respect to
unctional (6,14) and mortality (14) outcomes. The expla-
ation for the observed functional and mortality improve-
ents without concomitant definitive LVEF improvement
s unclear, but possible explanations include selective LVEF
chocardiographic assessment on adequately resynchronized
eats or interobserver variability in the published studies.
A variety of hypotheses may be postulated to explain the
ortality and functional benefits with AVNA in CRT-AF
atients. AVNA is believed to improve cardiac systolic
unction not only by lowering the ventricular rate and
egularizing the ventricular rhythm (24,25) but also by
mproving the quality of resynchronization by diminishing
he burden of conducted and fused ventricular beats (22). Inour study, benefits seem to have occurred despite reasonablyRe T
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mean BVP% in the medical rate control CRT-AF patients
in the 6 studies was 82% (Table 1). It should be noted,
however, that details of device-programming algorithms
used to enhance biventricular capture were not generally
reported.
Recent findings using 12-lead Holter monitoring of
CRT-AF patients suggest that the biventricular paced
percentage from device diagnostics may significantly over-
estimate the efficacy of truly “clean” biventricular paced
beats in this group (20). The findings of our study would
correlate with this finding, by suggesting that achieving
near to complete resynchronization with AVNA is highly
important.
Other reports have documented a favorable relationship
between an increased BVP% and improved clinical out-
comes in CRT patients. Hayes et al. (26) reported HF
outcomes in 30,000 patients with the LATITUDE re-
mote monitoring system. Patients paced 100% had a 27%
reduction in mortality compared with all other groups,
hereas patients paced 95% had a 35% increase in
mortality. Koplan et al. (27) analyzed HF outcomes in
1,812 predominantly CRT-SR patients from the CRT
RENEWAL and REFLEX trials. In subgroup analysis of
patients with a history of atrial arrhythmia, subjects with
92% BVP% had a hazard ratio of HF events or all-cause
mortality of 0.44 compared with subjects receiving 92%
BVP%. No increment, however, was found with increased
percentage of pacing beyond 92%. Most recently, Santini et
al. (28) examined HF outcomes in 1,193 real-world patients
implanted with CRT defibrillation devices. Device-detected
atrial tachycardia/fibrillation episodes lasting 10 min were
strongly associated with a 2-fold increase in the composite
death/HF hospitalization endpoint.
AVNA is a long-established therapy for the maintenance
of ventricular rate control in AF patients. One possible
reason why AVNA has not been more widely adopted in the
CRT-AF cohort is a perceived fear of pacemaker depen-
dency. However, in the CRT setting, the presence of the
additional left ventricular lead (especially bipolar left ven-
tricular leads) should reduce the risk associated with loss of
ventricular capture. Furthermore, complications associated
with AVNA due to loss of pacemaker function are very rare
and were not reported in the current studies.
Study limitations. The results of this report were compiled
using meta-analysis of primarily observational data, which
for the most part was retrospectively collected, rather than
randomized controlled trial data. Significant differences in
baseline characteristics were noted between AVNA– and
AVNA patients in a number of studies. The majority of
studies involved nonblinded recruitment and assessment of
study outcomes, and limited documentation of complete-
ness of follow-up. Nonetheless, the technique of meta-
analysis is accepted in the literature to aggregate results from
observational data to facilitate rapid synthesis of available
evidence and generation of new hypotheses. The dataavailable were compiled from a limited number of usable but
relatively small studies. In addition, the limitation of includ-
ing data only from published studies may lead to a risk of
publication or “file drawer” bias. In particular, all-cause
mortality or cardiovascular mortality data were available in
only 3 studies. The small number of studies also reduced the
opportunity for more detailed subgroup analyses to explore
for sources of heterogeneity. Nonetheless, a consistent trend
toward clinically significant reductions in all-cause mortality
and cardiovascular mortality with AVNA was observed in
the available studies. Furthermore, improved functional
capacity with AVNA was observed among the majority of
studies included, suggesting that AVNA in CRT-AF pa-
tients is worthy of investigation in a randomized controlled
trial.
Conclusions
AVNA in CRT-AF patients was associated with reductions
in all-cause mortality and cardiovascular mortality and
improvements in NYHA functional class. To confirm these
data, prospective evaluation of AVNA in CRT-AF patients
by randomized controlled trial is warranted.
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